secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001437749-22-012086
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M
---------------------------------------------------------------------

- Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.
- Net income $0.8M ($0.03 diluted EPS) vs $1.2M ($0.04) in prior-year quarter.
- Nine-month revenue $43.0M, down 7.6%; net income $2.3M vs $3.5M.
- Revenue decline attributed to normalization of customer safety stock from COVID-19 pandemic.
- Two largest contract manufacturing customers still represent ~91% of total revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/0001437749-22-012086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/inbp20220511_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-012086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer